Open-source automated insulin delivery (AID) systems in patients with type 1 diabetes was studied in the CREATE trial and is discussed by Dr Martin de Bock (University of Otago, Christchurch, New Zealand). Open-source AID systems were developed by people with diabetes and shared openly. They combine an insulin pump, continuous glucose monitor and an algorithm that adjusts insulin delivery automatically every five minutes with the purpose of keeping glucose levels in target range.
The abstract entitled ‘The CREATE Trial: Randomized Clinical Trial Comparing Open-Source Automated Insulin Delivery with Sensor Augmented Pump Therapy in Type 1 Diabetes‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Could you give us a brief overview of open-source automated insulin delivery systems (AID) and sensor-augmented pump therapy? (0:15)
- What were the aims, design and patient population of the CREATE trial? (0:50)
- How did the two treatment arms compare in terms of time in range? (1:23)
- What were study findings in terms of hypoglycaemia, diabetic ketoacidosis events, and treatment discontinuation? (1:51)
- Which patients were most likely to benefit from AID? (2:16)
Disclosures: Martin de Bock has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!